RHYTHM PHARMACEUTICALS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-196.5M | $-260.6M | $-184.7M | $-181.1M | $-69.6M | $-134.0M | $-140.7M | $-74.1M |
| Depreciation & Amortization | $500.0K | $700.0K | $900.0K | $896.0K | $816.0K | $690.0K | $834.0K | $442.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | $855.0K | $774.0K | $342.0K | — | — | — |
| Stock-Based Compensation | $66.8M | $39.7M | $32.6M | $19.8M | $20.8M | $17.5M | $11.9M | $6.4M |
| Net Cash from Operating Activities | $-115.7M | $-113.9M | $-136.2M | $-173.4M | $-146.0M | $-122.0M | $-122.8M | $-62.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $953.0K | $0 | $47.0K | $281.0K | $434.0K | $214.0K | $3.4M | $722.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-137.2M | $-48.2M | $-5.7M | $28.0M | $-62.2M | $158.5M | $-28.0M | $-87.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $218.0M | $191.2M | $74.4M | $213.8M | $166.5M | $2.0M | $163.5M | $164.7M |
| Net Change in Cash | $-34.8M | $29.2M | $-67.6M | $68.4M | $-41.7M | $38.6M | $12.8M | $15.5M |
| Free Cash Flow | $-116.6M | $-113.9M | $-136.2M | $-173.7M | $-146.4M | $-122.2M | $-126.1M | $-62.8M |